Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonists such as an exendin-4 has direct beneficial effects on the cardiovascular system. However, their effects on atherosclerogenesis have not been elucidated. The aim of this study was to investigate the effects of GLP-1 on accumulation of monocytes/macrophages on the vascular wall, one of the earliest steps in atherosclerogenesis. RESEARCH DESIGN AND METHODS: After continuous infusion of low (300 pmol · kg−1 · day−1) or high (24 nmol · kg−1 · day−1) dose of exendin-4 in C57BL/6 or apolipoprotein E–deficient mice (apoE−/−), we evaluated monocyte adhesion to the endothelia of thoracic aorta and arteriosclerotic lesions around the aortic valve. The effects of exendin-4 were investigated in mouse macrophages and human monocytes. RESULTS: Treatment with exendin-4 significantly inhibited monocytic adhesion in the aortas of C57BL/6 mice without affecting metabolic parameters. In apoE−/− mice, the same treatment reduced monocyte adhesion to the endothelium and suppressed atherosclerogenesis. In vitro treatment of mouse macrophages with exendin-4 suppressed lipopolysaccharide-induced mRNA expression of tumor necrosis factor-α and monocyte chemoattractant protein-1, and suppressed nuclear translocation of p65, a component of nuclear factor-κB. This effect was reversed by either MDL-12330A, a cAMP inhibitor or PKI14-22, a protein kinase A–specific inhibitor. In human monocytes, exendin-4 reduced the expression of CD11b. CONCLUSIONS: Our data suggested that GLP-1 receptor agonists reduced monocyte/macrophage accumulation in the arterial wall by inhibiting the inflammatory response in macrophages, and that this effect may contribute to the attenuation of atherosclerotic lesion by exendin-4.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17]”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“Within the cardiovascular system, GLP-1 receptors are expressed on endothelial cells, monocytes, macrophages, and vascular smooth muscle cells (VSMCs) [9].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Similar to lung and pancreatic -cells (24), mice peritoneal macrophages and vascular smooth muscle cells abundantly expressed GLP-1 receptor protein, and the expression level was higher than in freshly isolated endothelial cells.”
ResultGu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., & Rollins, B. J. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80139-2 · Cited by 1,575 · cited 1×
“Both TNF- – and MCP-1–deficient mice have significantly reduced atherosclerotic lesions (29,30).”
BackgroundA major role for VCAM-1, but not ICAM-1, in early atherosclerosis
Cybulsky, M. I., Iiyama, K., Li, H., Zhu, S., Chen, M., Iiyama, M., Davis, V., Gutierrez-Ramos, J.-C., Connelly, P. W., & Milstone, D. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11871 · Cited by 1,217 · cited 2×
“The adhesion of circulating monocytes to the intimal endothelial cells is thought to be one of the earliest events in the complex pathological process of atherosclerogenesis (14; 15).”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“In vascular endothelial cells, GLP-1 stimulates NO production, which may explain the vasodilatory effects in mesenteric arteries (11) and pulmonary artery rings (12).”
BackgroundNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundEbato, C., Uchida, T., Arakawa, M., Komatsu, M., Ueno, T., Komiya, K., Azuma, K., Hirose, T., Tanaka, K., Kominami, E., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.009 · Cited by 774 · cited 2×
“) or rabbit anti–glyceraldehyde-3-phosphate dehydrogenase antibody (Cell Signaling Technology, Beverly, MA) as described previously (16).”
BackgroundMethodSelf-citationNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundKolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552 · cited 1×
“In addition, GLP-1 has other effects that may improve the pathophysiology of the diabetic state, such as suppression of glucagon secretion (2), inhibition of gastrointestinal secretion and motility (4), and inhibition of food intake (5).”
BackgroundBrubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 540 · cited 2×
“It was reported previously that the main effects of GLP-1 are mediated through the activation of adenylate cyclase and the production of cAMP (25).”
BackgroundNikolaidis, L. A., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., Stolarski, C., Shen, Y.-T., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000139339.85840.dd · Cited by 514 · cited 1×
“With regard to the heart, exogenous administration of GLP-1 and exendin-4 has direct beneficial effects, such as improvement of left ventricular performance after myocardial infarction (6,7) and protection against ischemia (8,9).”
BackgroundInhibition of Tumor Necrosis Factor-α Reduces Atherosclerosis in Apolipoprotein E Knockout Mice
Brånén, L., Hovgaard, L., Nitulescu, M., Bengtsson, E., Nilsson, J., & Jovinge, S. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000143933.20616.1b · Cited by 495
Monocyte Chemoattractant Protein-1 Accelerates Atherosclerosis in Apolipoprotein E-Deficient Mice
Aiello, R. J., Bourassa, P.-A. K., Lindsey, S., Weng, W., Natoli, E., Rollins, B. J., & Milos, P. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.6.1518 · Cited by 466 · cited 1×
“Furthermore, forced expression of TNF- and MCP-1 in leukocytes promotes advanced atherosclerotic lesions (29,31).”
BackgroundKolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434 · cited 1×
“Indeed, treatment with exendin-4 at concentrations observed during treatment of humans (27,28) reduced the expression of inflammatory mediators TNF- and MCP-1 in activated macrophages.”
BackgroundWeber, C., Erl, W., Weber, K. S. C., & Weber, P. C. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00324-0 · Cited by 411 · cited 1×
“Activation of monocytes by cytokines, chemokines, hypercholesterolemia, and hyperglycemia leads to increased expression of this integrin, and increased monocyte expression of CD11b correlates with adhesion of these cells to the endothelium in patients with hypercholesterolemia (37).”
BackgroundExendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats
Szayna, M. (2000) · Endocrinology · doi:10.1210/en.141.6.1936 · Cited by 303 · cited 1×
“In addition, GLP-1 has other effects that may improve the pathophysiology of the diabetic state, such as suppression of glucagon secretion (2), inhibition of gastrointestinal secretion and motility (4), and inhibition of food intake (5).”
BackgroundInsulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
Parkes, D. G., Pittner, R., Jodka, C., Smith, P., & Young, A. (2001) · Metabolism · doi:10.1053/meta.2001.22519 · Cited by 241 · cited 1×
“3 he glucagon-like peptide-1 (GLP-1) is a hormone secreted from the L cells of the small intestine and stimulates glucose-dependent insulin response (1-3).”
BackgroundAronoff, D. M., Canetti, C., Serezani, C. H., Luo, M., & Peters-Golden, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.595 · Cited by 241 · cited 1×
“These data suggest that exendin-4 regulates inflammatory response of macrophages via the cAMP/PKA pathway, which inhibits proinflammatory cytokine production as reported recently (35,36).”
BackgroundA Simple Method of Isolating Mouse Aortic Endothelial Cells
Kobayashi, M., Inoue, K., Warabi, E., Minami, T., & Kodama, T. (2005) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12.138 · Cited by 238 · cited 1×
“Mouse aortic vascular endothelial cells were isolated and cultured as described previously (17).”
Greig, N. H., Holloway, H. W., De Ore, K. A., Jani, D., Wang, Y., Zhou, J., Garant, M. J., & Egan, J. M. (1999) · Diabetologia · doi:10.1007/s001250051111 · Cited by 189 · cited 1×
“3 he glucagon-like peptide-1 (GLP-1) is a hormone secreted from the L cells of the small intestine and stimulates glucose-dependent insulin response (1-3).”
BackgroundLiu, H., Dear, A. E., Knudsen, L. B., & Simpson, R. W. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0468 · Cited by 187 · cited 2×
“Quantification of mRNA expression in the thoracic aorta showed that exendin-4 treatment significantly downregulated intercellular adhesion molecule-1 (ICAM-1) and tended to downregulate VCAM-1 (Fig.”
BackgroundMogi, C., Tobo, M., Tomura, H., Murata, N., He, X.-D., Sato, K., Kimura, T., Ishizuka, T., Sasaki, T., Sato, T., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803466 · Cited by 174 · cited 1×
“These data suggest that exendin-4 regulates inflammatory response of macrophages via the cAMP/PKA pathway, which inhibits proinflammatory cytokine production as reported recently (35,36).”
BackgroundGLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery
Richter, G., Feddersen, O. C., Wagner, U., Barth, P. J., Göke, R., & Göke, B. (1993) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1993.265.4.l374 · Cited by 146 · cited 2×
“production, which may explain the vasodilatory effects in mesenteric arteries (11) and pulmonary artery rings (12).”
BackgroundNomiyama, T., Nakamachi, T., Gizard, F., Heywood, E. B., Jones, K. L., Ohkura, N., Kawamori, R., Conneely, O. M., & Bruemmer, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603436200 · Cited by 142
Self-citationThe Neuropeptide Vasoactive Intestinal Peptide Generates Tolerogenic Dendritic Cells
Delgado, M., González‐Rey, E., & Ganea, D. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7311 · Cited by 135 · cited 1×
“Nuclear protein extracts were isolated from peritoneal macrophages and the content of nuclear factor- B (NF- B) p65 was determined using a specific ELISA kit using the method recommended by the manufacturer (Imgenex, San Diego, CA) (22).”
MethodExendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes
Dupré, J., Behme, M. T., & McDonald, T. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032001 · Cited by 133 · cited 1×
“In addition, GLP-1 has other effects that may improve the pathophysiology of the diabetic state, such as suppression of glucagon secretion (2), inhibition of gastrointestinal secretion and motility (4), and inhibition of food intake (5).”
BackgroundYamada, H., Yoshida, M., Nakano, Y., Suganami, T., Satoh, N., Mita, T., Azuma, K., Itoh, M., Yamamoto, Y., Kamei, Y., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.171736 · Cited by 112 · cited 1×
“The cell density in each area was then calculated as the cell count (determined by an examiner blinded to the treatment regimen) divided by the total area (19-21).”
MethodSelf-citationKumashiro, N., Tamura, Y., Uchida, T., Ogihara, T., Fujitani, Y., Hirose, T., Mochizuki, H., Kawamori, R., & Watada, H. (2008) · Diabetes · doi:10.2337/db08-0144 · Cited by 109
Self-citationDelgado, M., & Ganea, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006923200 · Cited by 107
Izeboud, C. A., Monshouwer, M., van Miert, A. S. J. P. A. M., & Witkamp, R. F. (1999) · Inflammation Research · doi:10.1007/s000110050493 · Cited by 90
Gedulin, B. R., Smith, P., Prickett, K. S., Tryon, M. S., Barnhill, S. D., Reynolds, J., Nielsen, L. L., Parkes, D. G., & Young, A. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1795-2 · Cited by 82 · cited 1×
“Indeed, treatment with exendin-4 at concentrations observed during treatment of humans (27,28) reduced the expression of inflammatory mediators TNF- and MCP-1 in activated macrophages.”
BackgroundSwings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice
Mita, T., Otsuka, A., Azuma, K., Uchida, T., Ogihara, T., Fujitani, Y., Hirose, T., Mitsumata, M., Kawamori, R., & Watada, H. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.118 · Cited by 67 · cited 2×
“The cell density in each area was then calculated as the cell count (determined by an examiner blinded to the treatment regimen) divided by the total area (19-21).”
MethodSelf-citationShames, B. D., McIntyre, R. C., Bensard, D. D., Pulido, E. J., Selzman, C. H., Reznikov, L. L., Harken, A. H., & Meng, X. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6178 · Cited by 42
A new En face method is useful to quantitate endothelial damage in vivo
Azuma, K., Watada, H., Niihashi, M., Otsuka, A., Sato, F., Kawasumi, M., Shimada, S., Tanaka, Y., Kawamori, R., & Mitsumata, M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.013 · Cited by 31 · cited 1×
“The cell density in each area was then calculated as the cell count (determined by an examiner blinded to the treatment regimen) divided by the total area (19-21).”
MethodSelf-citationChong, Y. H., Shin, S. A., Lee, H. J., Kang, J. H., & Suh, Y. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00349-1 · Cited by 27 · cited 1×
“inhibited TNF-α production and its transcription in macrophage (32-34).”
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“This results in a reduction of monocyte accumulation in the vascular wall, as shown for example with exenatide [143].”
BackgroundChait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Autophagy—a key player in cellular and body metabolism
Kim, K. H., & Lee, M.-S. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.35 · Cited by 963
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Metadata
- Authors
- Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H.
- Affiliations
- Juntendo University (JP)
- Corresponding author
- Mita, Tomoya
- Watada, Hirotaka
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-01-12
- Volume
- 59
- Issue
- 4
- Pages
- 1030-1037
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2844811
- OpenAlex
- W2142097676
- Cited by
- 548
- References
- 38
- Citations by year
- 2026: 31 · 2025: 25 · 2024: 34 · 2023: 27 · 2022: 37 · 2021: 33 · 2020: 27 · 2019: 25 · 2018: 36 · 2017: 32 · 2016: 41 · 2015: 46 · 2014: 36 · 2013: 35 · 2012: 43
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- exendin-4, GLP-1 receptor agonists, monocyte adhesion, endothelial cells, atherosclerosis, macrophage accumulation, ApoE-deficient mice, NF-κB, TNF-α, MCP-1, cAMP signaling, protein kinase A, CD11b, inflammation
- MeSH terms
- Exenatide, Animals, Aorta, Cell Adhesion, Endothelium, Vascular, Flow Cytometry, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Islets of Langerhans, Liver, Lung, Male, Mice, Inbred C57BL, Monocytes, Peptides, Venoms, Reverse Transcriptase Polymerase Chain Reaction, Atherosclerosis, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.